$XRAY

Barber Michael J purchased $150K of XRAY

Barber Michael J purchased 15,175 shares of DENTSPLY SIRONA Inc. (XRAY) at $9.88 ($0.15M total) on 2026-06-11.

Original reporting
SEC EDGAR · Barber Michael J
Published Jun 15, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 10:57 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$XRAY
Neutral
medium confidence
Mentioned
$XRAY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XRAYNeutralLow
01

Why it matters

The newest fact is the director’s open-market purchase of 15,175 shares at $9.8850 on June 11, with holdings after the trade of 55,943 shares. No other company-specific news is included.

02

Market read

Traders may note the insider buy as a mild sentiment input, but there is no fundamental catalyst in the text to drive a decisive repricing.

03

What to watch

The article provides no context on prior insider activity, total holdings relative to typical behavior, or whether the buy was opportunistic versus routine.

Relevance 5/10Novelty 3/10Timing: filed June 15, transaction dated June 11

Background

The article is an SEC Form 4 insider transaction disclosure for Dentsply Sirona (XRAY).

Company-level read

Ticker impact

$XRAYNeutralMedium confidence
Context

Dentsply Sirona director Michael J Barber bought 15,175 shares in an open-market transaction worth about $150,005, per Form 4 filed June 15.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely short-lived.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying corporate event, guidance, or operational catalyst in the text.

Market effects

Minimal, as the disclosure does not indicate sector-wide changes or new regulatory/clinical developments.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, liquidity needs, or pre-planned personal strategies, so the signal may be weaker than it appears.

Key entities

  • DENTSPLY SIRONA Inc.

    Public company subject of the Form 4 insider transaction disclosure.

  • Barber Michael J

    Director who reported an open-market purchase of XRAY shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

Dentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.

$XRAYMed

Dentsply Sirona Reports Strong PrimeTaper EV Results

Dentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.

$XRAYMed

DENTSPLY SIRONA Q2 Earnings Call Highlights

Dentsply Sirona (NASDAQ:XRAY) reported Q2 segment sales declines amid uneven regional demand and higher operating expenses, including an $8 million FX headwind. Connected Technology Solutions sales were $239M, down 1.5%. Orthodontic and Implant Solutions revenue fell 13.2% to $197M. The company maintained 2026 net sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.

$XRAYMedAI 8/10

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.

$XRAYMedAI 8/10

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

Dentsply Sirona (XRAY) reported Q2 2026 adjusted EPS of 52 cents, down 1.6% YoY but above the Zacks Consensus estimate of 36 cents. Revenue fell 4.1% to $898 million. Wellspect Healthcare growth helped offset declines in other dental segments. The company kept 2026 net sales guidance at $3.5B-$3.6B and adjusted EPS at $1.40-$1.50.